TriangleHEALTH PROFESSIONAL · SOURCE READING
Tafasitamab plus lenalidomide
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Tafasitamab is a humanized anti-CD19 monoclonal antibody with a fucosylated Fc region to enhance antibody-dependent cellular cytotoxicity. Tafasitamab has been studied mostly in combination with lenalidomide.
Evidence (tafasitamab plus lenalidomide):
In a phase II study, 80 patients with SCT-ineligible relapsed or refractory DLBCL were treated with tafasitamab and lenalidomide. The study excluded patients with high-risk cytogenetics (MYC and BCL2 and/or BCL6 rearrangements) and those who had received more than four prior lines of therapy or prior CD19-directed therapy.[38]
Source links and citations
In a phase II study, 80 patients with SCT-ineligible relapsed or refractory DLBCL were treated with tafasitamab and lenalidomide. The study excluded patients with high-risk cytogenetics (MYC and BCL2 and/or BCL6 rearrangements) and those who had received more than four prior lines of therapy or prior CD19-directed therapy.[38]
The complete response rate was 43% and the objective response rate was 60%.
The FDA approved the combination of tafasitamab and lenalidomide for patients with relapsed or refractory DLBCL.[38][Level of evidence C3] It is unclear if using this CD19-directed therapy interferes with consolidation using CD19-CAR T cells.
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Independent clinical review pending · Not medical advice